<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01634893</url>
  </required_header>
  <id_info>
    <org_study_id>CTRC 11-71</org_study_id>
    <secondary_id>HSC20120203H</secondary_id>
    <nct_id>NCT01634893</nct_id>
  </id_info>
  <brief_title>Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors</brief_title>
  <official_title>A Phase I Dose-Escalation Trial of Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with recurrent, refractory or metastatic solid tumors have a dismal prognosis with&#xD;
      few viable treatment options. Hydroxychloroquine (HCQ) is an agent that has been widely used&#xD;
      to treat malaria. Because HCQ also inhibits autophagy, a process central to survival of&#xD;
      cancer in the face of metabolic stress, including the effects of anti-cancer therapy, it is&#xD;
      now in human cancer trials combined with other agents to attempt to boost the efficacy of&#xD;
      those agents. Autophagy inhibition improves the activity of sorafenib in hepatocellular&#xD;
      carcinoma.&#xD;
&#xD;
      Sorafenib is an oral multi-kinase inhibitor that blocks not only receptor tyrosine kinases&#xD;
      such as KIT, VEGFR and PDGFR but also serine/threonine kinases along the RAS/RAF/MEK/ERK&#xD;
      pathway.&#xD;
&#xD;
      The investigators propose to treat patients with refractory or relapsed solid tumors with&#xD;
      sorafenib, to boost its efficacy while attempting to mitigate its toxicity by combining with&#xD;
      HCQ.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity evaluated according to the common toxicity criteria for adverse events (AEs) (CTCAEv4.0)</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the toxicities of combining sorafenib plus HCQ in this patient population</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Refractory or Relapsed Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Sorafenib plus Hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of sorafenib combined with hydroxychloroquine (HCQ) to a maximum of sorafenib 400 mg PO BID plus HCQ 400 mg PO QD.&#xD;
Drugs are given on an intermittent schedule of days 1-5/week in a 28-day cycle.&#xD;
Sorafenib alone is given in cycle 1, and HCQ is added in cycle 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib combined with Hydroxychloroquine</intervention_name>
    <description>dose escalation of sorafenib combined with hydroxychloroquine (HCQ) to a maximum of sorafenib 400 mg PO BID plus HCQ 400 mg PO QD.&#xD;
Drugs are given on an intermittent schedule of days 1-5/week in a 28-day cycle.&#xD;
Sorafenib alone is given in cycle 1, and HCQ is added in cycle 2.</description>
    <arm_group_label>Sorafenib plus Hydroxychloroquine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Not on immune-modulating drugs, except those used as study drug premedication, unless&#xD;
             the principal investigator grants an exception (which exception must be documented in&#xD;
             writing)&#xD;
&#xD;
          -  Patients with relapsed or refractory solid tumors with no viable treatment options&#xD;
&#xD;
          -  Measurable disease within 30 days of study enrollment&#xD;
&#xD;
          -  Blood hemoglobin &gt; 8.5 gm/dl within 7 days of study enrollment&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1000/mm3 within 7 days of study enrollment&#xD;
&#xD;
          -  Platelet count &gt; 50,000/mm3 within 7 days of study enrollment&#xD;
&#xD;
          -  SGOT &lt;10x upper limit of normal within 7 days of study enrollment&#xD;
&#xD;
          -  No chemotherapy or radiation therapy in the 14 days prior to initiation of treatment&#xD;
             on this study. No other concurrent chemotherapy, surgery or radiation therapy during&#xD;
             this protocol except surgery or radiation therapy to control symptoms with concurrence&#xD;
             of the principal investigator.&#xD;
&#xD;
          -  No contraindication to any study treatment&#xD;
&#xD;
          -  No active major medical problems, including untreated or uncontrolled infections&#xD;
&#xD;
          -  If of reproductive potential, a negative urine or blood pregnancy test within 3 days&#xD;
             of study enrollment, and agreement to use adequate contraception. In relevant&#xD;
             subjects, pregnancy testing will continue monthly while on treatment unless the&#xD;
             subject is no longer able to become pregnant or there is sufficient justification&#xD;
             otherwise&#xD;
&#xD;
          -  Not breast feeding&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  ECOG performance status &lt; 2&#xD;
&#xD;
          -  Age 18+ years&#xD;
&#xD;
          -  No active substance abuse in the prior 6 months&#xD;
&#xD;
          -  Not on digoxin or cimetidine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication or hypersensitivity to any study drug or its components or excipients&#xD;
&#xD;
          -  Current pregnancy or breast feeding&#xD;
&#xD;
          -  Inability to document adequate contraception if a female of reproductive potential&#xD;
&#xD;
          -  Chemotherapy or radiation therapy within the 14 days prior to initiation of study&#xD;
             treatment&#xD;
&#xD;
          -  Prior treatment with sorafenib. Prior HCQ use is not an exclusion.&#xD;
&#xD;
          -  Life expectancy &lt; 6 months&#xD;
&#xD;
          -  ECOG performance status &gt; 2&#xD;
&#xD;
          -  Symptomatic coronary artery disease (including uncontrolled angina, congestive heart&#xD;
             failure, and the like)&#xD;
&#xD;
          -  Uncontrolled hypertension (diastolic BP consistently &gt;100 mm Hg or systolic BP&#xD;
             consistently &gt;160 mm Hg on a regular basis)&#xD;
&#xD;
          -  Uncontrolled, symptomatic cardiac arrhythmia&#xD;
&#xD;
          -  Active substance abuse in the prior 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tyler Curiel, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health Science Center San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center at UTHSCSA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>July 3, 2012</study_first_submitted>
  <study_first_submitted_qc>July 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2012</study_first_posted>
  <last_update_submitted>March 24, 2016</last_update_submitted>
  <last_update_submitted_qc>March 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Refractory or Relapsed Solid Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

